SkinBioTherapeutics (LON:SBTX) Shares Down 10.4% – Here’s What Happened

SkinBioTherapeutics plc (LON:SBTX) was down 10.4% during mid-day trading on Friday . The stock traded as low as GBX 7.55 and last traded at GBX 7.84. 830,164 shares changed hands during trading, a decline of 65% from the average daily volume of 2,352,551 shares. The stock had previously closed at GBX 8.75.

SkinBioTherapeutics Stock Performance

The stock has a fifty day simple moving average of GBX 10.19 and a two-hundred day simple moving average of GBX 9.97. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14. The stock has a market cap of £20.32 million, a price-to-earnings ratio of -49.00 and a beta of 0.10.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.